The New Arms Race: Pharma Giants Bet Big on Gene Therapies as Hemophilia Market Poised for Transformative Decade
The hemophilia treatment landscape, long defined by lifelong intravenous infusions of clotting factors, is undergoing a…
End of content
End of content